1.. Introduction {#S1}
================

1.1.. Asthma {#S2}
------------

Asthma is defined as a chronic inflammatory condition characterized by episodic shortness of breath with wheeze. It is characterized by intermittent airflow obstruction, airway hyperreactivity, and increased production of mucus. According to the U.S. Centers for Disease Control and Prevention (CDC), an estimated 24.6 million Americans, including over 6 million children, have asthma. The estimated annual cost of asthma care in the U.S. is roughly \$56 billion and asthma remains a leading cause of missed work and school. According the Global Asthma Network (GAN), it is estimated that over 330 million people worldwide have this disease and asthma is ranked in the top 20 of "most important disorders" due to chronicity of illness. Thus, asthma remains a universal and significant public health concern.

Asthma is a complex, heterogeneous disease in which several variants exist, each with a different underlying immunopathology. Historically asthma was characterized as a TH2-centric disease marked by high levels of IgE and eosinophilic infiltration into the lung. While a majority of patients with asthma do have a history of allergic disease, certain groups of patients present clinically with an asthma phenotype in the absence of atopy. The different underlying pathophysiological mechanisms suggest the need for additional molecular and genetic characterizations, the development of targeted, customized treatment modalities, and the value of biomarkers to improve diagnosis and treatment. Recently, work has highlighted different asthma endotypes that are segregated by clinical characteristics ([@R56]) or through the use of genetic markers found in sputum ([@R64]). This clinical cluster modeling has enabled us to categorize endotypes of asthmatics into groups and better understand more of the molecular underpinnings of the disease process. The development of these clinical algorithms has advanced the goal of using precision-based medicine approaches for asthma. But despite these efforts, there are still clusters of patients with severe asthma in which drugs are lacking and specific biomarkers are unavailable.

1.2.. Sphingolipids {#S3}
-------------------

In 1884, Dr. Johann L.W. Thudichum isolated a unique lipid moiety from the brain he called "sphingosine" which he named after the Great Sphinx due to its perplexing chemical nature ([@R82]). This fatty amino alcohol serves as the backbone of a ubiquitous class of lipids found across various species called sphingolipids. Living up to the name, sphingolipids remain an enigmatic class of lipids involved in a host of biological functions ranging from serving as key cellular membrane lipids to acting as critical signaling molecules. To date sphingolipids have been studied across various human conditions ranging from neurological disorders to cancer to infection to autoimmunity. Sphingolipids exhibit great structural and functional diversity. The simple sphingolipid ceramide is often referred to as the nexus of sphingolipid metabolism due to its pivotal role in sphingolipid accumulation through *de novo* synthesis as well as serving as a predecessor for other sphingolipid family members ([@R26]). Whereas complex sphingolipids such as cerebrosides are glycosphingolipids and defects in their catabolism, as the name suggests, have significant effects on the nervous system ([@R17]). Sphingolipid metabolites such as sphingosine-1-phosphate (S1P) and ceramide-1-phosphate (C1P) are potent bioactive mediators that are critical, especially in relation to immune responses and inflammatory processes as they regulate immune cell migration and play a role in cancer immunopathology ([@R24]; [@R76]).

In addition to structure and function, the regulation of these lipids is also complex. There are multiple enzymatic processes that regulate the interconversion amongst these lipid species and each enzyme serves as another layer of control in maintaining homeostasis. The year 1993 was a pivotal year in sphingolipid research as two seminal papers, both appearing in Nature, showed that sphingolipids could both induce cell death ([@R58]) and cell proliferation ([@R60]). These papers highlighted differing and opposing roles of ceramide and S1P respectively. Three years later, the Spiegel laboratory uncovered the molecular cross-talk between these pathways and coined the term the "sphingolipid rheostat" ([@R10]) which provided further insight into the regulation and activity of this complex class of lipids.

1.3.. Sphingolipids in the lung {#S4}
-------------------------------

The notion that sphingolipids could play a role in pulmonary pathophysiology was first alluded to in the 1940s when Thannhauser et al. isolated and described lipid species in various animal lungs ([@R80]). Almost twenty years later, Matthews et al. showed that the secretions from patients with either cystic fibrosis (CF) or bronchiectasis had a much higher lipid content when compared to controls ([@R49]). It was this work that led Harlan et al. to examine pulmonary secretions to better understand the contributions of lipids other than phosphatidylcholine, the major lipid species found in pulmonary surfactant ([@R27]). Years later Sahu and Lynn showed that the bronchoalvealoar lavage (BAL) fluid from patients with asthma contained sphingomyelin species as well as glycolipids in the form of hexosylceramides which served as some of the first evidence for a role of sphingolipids in asthma ([@R70]).

1.4.. Environmental causes of asthma {#S5}
------------------------------------

The National Institute of Environmental Health Sciences (NIEHS) has stated that the contribution of environmental allergens to the pathogenesis of asthma is a serious public health concern and research is warranted in the field. Air pollution has been shown to be both a contributing factor to asthma development ([@R89]) and asthma exacerbations ([@R22]). Diesel exhaust has been shown to a major player in the environmental influences of asthma and diesel exhaust particles have been shown to upregulate both ceramide production and sphingosine kinase 1 (SphK1) activity in bronchial epithelial cells ([@R73]). Inhalation of carbonaceous pollutants in the form of carbon nanoparticles has also been linked to pulmonary dysfunction and exposure to these xenobiotic agents has been shown to alter ceramide accumulation in lung epithelial cells leading to aberrant inflammatory response generation in the lung ([@R65]). Cigarette smoke either by direct or secondhand exposure have all been linked to asthma development and exacerbation ([@R81]). Both conventional and electronic cigarette (e-cigs) vapors have shown to disrupt pulmonary endothelial barrier integrity by upregulating intracellular ceramide production ([@R72]) in a neutral sphingomyelinase 2 (nSmase2) dependent fashion ([@R45]) as well as alter autophagy by inducing accumulation of lactosylceramide in lipid rafts ([@R3]).

There is a mounting body of evidence that infectious agents also contribute to asthma incident and illness ([@R12]). Upper respiratory infections are the most common cause of acute illness across the lifespan. Certain pathogens have been strongly linked to the initiation of asthma such as respiratory syncytial virus (RSV) and human rhinovirus (HRV). In fact there is a significant increase in the likelihood that a child with develop asthma if they are infected with both HSV and HRV in the first three years of life (OR = 10.0) ([@R5]). Both of these viruses rely heavily on sphingolipid species for viral entry into the cell. RSV utilizes ganglioside GM1 for both viral entry and propagation ([@R77]) and has to ability to activate both neutral ceramidase and SphK1 in the lung ([@R55]). The activation of these enzymes leads to both the downregulation of ceramide production and the upregulation of S1P production which in turns prolongs lung epithelial survival of virally infected cells. HRV also highjacks the host sphingolipid machinery. HRV has been shown to activate the acidic sphingomyelinase and induce the formation of ceramide-rich platforms to facilitate further viral entry ([@R19]). While these two viral culprits are most closely linked to asthma initiation, other viral species such as influenza have been strongly linked with exacerbations of asthma resulting in significant morbidity and mortality ([@R5]). Interestingly influenza also affects sphingolipid signaling by inhibition of S1P lyase, thus resulting in increased S1P levels in the infected cell ([@R87]).

Bacterial infections have also been linked to asthma. Numerous studies have begun to examine alterations in the host microbiome and microbial exposures as it pertains to asthma development and severity ([@R71]) whereas atypical pulmonary infections have been shown to aggravate established asthma. A major pathogen responsible for community acquired pneumonia, *Mycoplasma pneumoniae*, induces profound alterations in host cell sphingolipid composition by inducing activation of serine palmitoyltransferase (SPT), the rate limiting step in de *novo* sphingolipid production ([@R90]). Fungi are also a significant environmental contributor to the disease burden of asthma and unlike most prokaryotes, multiple fungal species are capable of producing their own sphingolipids. In fact, fungal derived sphingolipids are found to play a role in their pathogenicity as is the case with *Aspergillis niger* ([@R74]) and inhalation of non-pathogenic fungal species such as *Alternaria alternata* can induce sphingolipid production from host airway epithelial cells ([@R88]).

Allergens themselves can also influence sphingolipid signaling and contribute to asthma pathogenesis. In fact, it has been shown that pollen contains a wide array of sphingolipids ([@R33]). House dust mite (HDM) is a prevalent antigen and a leading contributor of asthma. HDM is thought to be one of the most significant sources of indoor antigens associated with human asthma ([@R13]) and it has been estimated that 50--85% of asthmatics world-wide are HDM allergic ([@R21]). We recently reported that administration of HDM induces ceramide production in the murine lung and results in allergic airway disease ([@R62]). Lastly, there has been robust research on how exogenous sphingolipids can directly activate immune cells and leads to pulmonary inflammation. Alpha-galactosylceramide (a-GalCer) is a synthetic sphingolipid derivative from sphingolipid species produced from the marine sponge *Agelas mauritanianus*. A-GalCer is widely used in the laboratory setting as it is a potent activator of invariant natural killer T cells (iNKT cells) and has shown a to play a role in the pathogenesis of asthma ([@R35]) by exaggerating T~H~2 immune responses.

Taken together there is mounting evidence demonstrating that environmental triggers can have a profound effect on asthma. The role of sphingolipids in asthma initiation is not well defined however the strong body of literature suggests that it is these early activation events resulting in altered sphingolipid pathways that may be a key aspect of asthma development and severity.

1.5.. Genetic causes of asthma {#S6}
------------------------------

Aside from environmental contributions, there is also a strong genetic component to asthma. Several genome-wide association studies (GWAS) have demonstrated that polymorphisms in a region of chromosome 17q21, which includes the ORM (yeast)-like protein isoform 3 (ORMDL3) gene, contribute to both childhood and adult-onset asthma in a number of ethnically diverse populations ([@R18]; [@R53], [@R54]; [@R84], [@R85]; [@R86]). In fact, identification of ORMDL3 as an asthma susceptibility gene ignited both a new era of research into genetics as well as sphingolipid regulation in the asthma field. However, despite the enthusiasm, the mechanism by which ORMDL3 contributes to asthma pathogenesis is not well understood. ORMDL3 is the only member of the evolutionary conserved family of three endoplasmic reticulum localized proteins, ORMDL1--3, that has been linked to asthma. In yeast, the ORM proteins negatively regulate sphingolipid homeostasis in response to physiological needs by forming a complex with and inhibiting serine palmitoyltransferase (SPT) ([@R4]; [@R25]). Recent studies suggest that ORMDL3 also regulates ceramide biosynthesis in mammalian cells ([@R75]). Because ORMDL3 polymorphisms are associated with its high expression ([@R37]; [@R86]), it was suggested that this expression would correlate with decreased sphingolipid biosynthesis in asthma ([@R88]). Yet elevations of sphingolipids rather than reductions have been linked to inflammatory responses *in vitro*. Additionally, elevated levels of ceramide and S1P have been reported in lung diseases, including asthma, thus presenting a biological paradox ([@R47]; [@R61]; [@R68]). Work by our group and others imply that genetic regulation of sphingolipid homeostasis in asthma is much more complex than initially thought. We showed that although small increases in ORMDL3 expression decrease ceramide levels, in agreement with its evolutionary conserved role as a negative regulator of SPT, remarkably however, higher expression in lung epithelial cells and macrophages increased ceramide production by the recycling/salvage pathway ([@R62]). While our group has focused on the ORMDL3 regulation of sphingolipid biosynthesis itself, other groups have highlighted a role for this protein in the unfolded protein response ([@R46]), airway remodeling ([@R7]), and airway smooth muscle biology ([@R6]) in asthma, again emphasizing the enigmatic role that sphingolipids may play in the complex immunopathology of asthma.

1.6.. Mast cells {#S7}
----------------

First described in 1878 by Paul Ehrlich, mast cells (MC) are an important immune cell of the myeloid lineage. MCs are key sentinel cells in the lung that release a host of inflammatory mediators including vasoactive amines, lipids, proteoglycans, proteases, and cytokines upon activation. These MC mediators are the culprits for the outward appearances of allergic responses and can be attributed to the major clinical symptoms of asthma including increased vascular permeability, increased airway smooth muscle contractions, and increased mucus production ([@R11]). MCs are most notable for their role in asthma given their primary mechanism of action: IgE mediated responses via FcER1, the high affinity IgE receptor. Upon crosslinking of this receptor, MCs degranulate to release preformed mediators such as histamine and become activated to induce the synthesis and release of neoformed mediators responsible for the late phase responses such as IL-4.

Aside from canonical IgE signaling, it is now appreciated that the MCs have a critical and multifaceted role in asthma immunopathology. MCs secrete a host of chemokines and cytokines that recruit effector cells into the lung such CXCL1 ([@R14]) and CCL11 ([@R28]) to recruit neutrophils and eosinophils respectively. MCs can serve as antigen presenting cells to naïve T cells ([@R78]) and iNKT ([@R30]) cells in the microenvironment and enhance B cell IgE production via upregulation of CD40L to ([@R31]) to enhance local T~H~2 immune responses in the lung. Despite their fundamental role in asthma, effective therapies are lacking to specifically target MCs. Since MCs have historically been studied in the setting of IgE mediated allergic airway disease, Xolair (omalizumab), a monoclonal antibody that blocks IgE binding to its high affinity receptor has been developed and is now available clinically. It has shown promise in patients with severe asthma; however, unfortunately, initial enthusiasm regarding Xolair's potential to reduce asthma symptomology has diminished due to its effects primarily on extreme cases of atopic asthma and its high cost ([@R57]). Furthermore, recent research has highlighted roles for IgE-independent actions of MCs and the role of mast cells in innate immune responses; thus, examining multiple facets of MC function in the context of asthma may yield better therapeutic targets.

1.7.. Mast cells and sphingolipids {#S8}
----------------------------------

The interplay between sphingolipid signaling and mast cell biology has long been appreciated, with the first report that sulfatides could be isolated from neoplastic mast cells in 1960 ([@R20]). Some 20 years later, Curtain et al. demonstrated that sensitizing rat peritoneal mast cells resulted in glycosphingolipid clustering in the plasma membrane which was critical for degranulation ([@R9]). Katz et al. extended these studies to show that sphingolipid reorganization was not only a marker of mast cell activation but was useful in discerning subtypes of murine mast cells ([@R40]; [@R41]). It was later shown that the presence of these surface expressed sphingolipids could act of signaling receptors as well. Activation of gangliosides through binding of a specific monoclonal antibody, mab AA4, resulted in similar morphological and intracellular activation of MCs as compared to canonical IgE signaling ([@R59]) and that these two signaling pathways shared Lyn as a common signaling intermediate ([@R51]). While lipid moieties such as phosphoinositides and diacylglycerols had been implicated as second messengers in cell signaling, some of the first evidence that sphingolipid species could also act as signaling molecules in the immune system came in 1999. Choi et al. showed that FcER1 activation led to activation of SphK1 which in turn led to production of S1P as a primary mechanism for calcium mobilization in mast cells ([@R29]).

Sphk1 has been shown to be a fundamental kinase involved in MC biology. SphK1 rapidly phosphorylates sphingosine to form S1P and that S1P can either act as an intracellular switch for the activation of MCs or can be released from the cell to act extracellularly ([@R67]) via ATP binding cassette transporter 1 (ABCC1) ([@R52]). With the discovery that S1P can bind a cluster of G protein coupled receptors on the cell surface of various cells ([@R44]) the concept of "inside-out" S1P signaling emerged ([@R79]). S1P has been shown to transactivate MC S1P receptors 1 and 2 (S1PR1 and S1PR2) and be involved in MC migration and degranulation respectively ([@R38]). Recent data has highlighted a role for SIPR4 in anaphylactic reactions ([@R43]), again highlighting the many roles of MCs and S1P signaling in immune responses.

While S1P has been shown to act as positive stimuli in terms of MC responses, ceramide and sphingosine function as negative regulators of MC biology, against reiterating the role of the "sphingolipid rheostat" in maintaining homeostasis. The addition of exogenous sphingosine diminished FcER1 mediated SphK1 activation ([@R67]) and along these lines it has been shown that sphingosine directly blocks calcium release-activated calcium current (ICRAC) in RBL cells ([@R48]). Exogenous ceramide has been shown to induce MC apoptosis ([@R34]), inhibit LPS induced cytokine production ([@R8]), and negatively regulate mast cell activation ([@R36]).

While clearly other cell types are involved in the immunopathology of asthma, the focus on MCs was shown as an exemplar for the complex role of sphingolipid biology in this disease ([Fig. 1](#F1){ref-type="fig"}). Thus, better understanding of the role of sphingolipid biology in mast cell responses may provide valuable insight into the development of novel therapeutics for disease management.

1.8.. Targeting sphingolipids for disease control {#S9}
-------------------------------------------------

While the majority of the data highlighted in this review show a correlative association amongst sphingolipids and asthma disease processes, there is also compelling evidence that sphingolipids exert a direct causative effect in the lung. Both the direct administration of either S1P ([@R1]; [@R16]) or ceramide ([@R47]) induce airway smooth muscle contraction.

The utility of sphingolipid species as viable biomarkers is also an active area of investigation. The Spiegel laboratory has shown that both S1P ([@R69]) and ceramide ([@R62]) are elevated in the airway of patients with asthma. However, these studies did not take into account endotypes of asthma nor were validated biomarkers of disease such as periostin or FeNO assessed. Other groups have shown plasma S1P to be an asthma biomarker associated with adult disease control ([@R50]) and severity ([@R68]). One severe endotype of asthma is aspirin exacerbated respiratory disease (AERD). Recently Trihn et al. demonstrated that S1P is a potential biomarker for AERD ([@R83]). Additionally sphingolipid levels in the serum of pediatric patients have also been examined and illustrate an upregulation of various ceramide species associated with childhood asthma ([@R63]). Taken together, these highlight the importance of better understanding of the role of sphingolipid biology in specific asthma endotypes.

Lastly there have been several studies in animal models that suggest pharmacologic targeting of sphingolipid species may hold promise as a novel class of asthma therapeutics. The use of myriocin, which inhibits SPT, has shown mixed responses in the literature. There have been reports that myriocin exacerbates AHR both in the presence ([@R15]) and absence ([@R88]) of allergen challenge. On the other hand Oyeniran et al. showed a significant abrogation of HDM mediated allergic airway disease specifically in relation to AHR ([@R62]). Part of the discrepancies across these studies could be related to pharmacokinetics of the drug itself and/or sphingolipid signaling. Oyeniran et al. utilized the inhibitor only in the later stages of allergen challenge and the drug was administered I.P. due to drug solubility issues. The two prior studies administered myriocin directly into the lung parenchyma and at different dosing strategies. Thus, targeting SPT as a viable mechanism of asthma control will need further investigation before these findings can be translated from mouse to man.

On the other hand, greater pharmacologic success has been found in relation to targeting either SphKs or S1P itself. FTY720 is a derivative of myriocin and a structural analog of sphingosine. It is a prodrug that is phosphorylated upon entry into the cell by SphK. It is this phosphorylated form that acts as a potent agonist of SIPRs. However newer studies have also shown that FTY720 may exert pleotropic effects on cellular responses by inhibiting ceramide synthases ([@R2]) or acting as a histone deacyltase inhibitor ([@R23]). Intranasal administration of FTY720 has shown to alter dendritic cell function ([@R32]), inhibit airway remodeling ([@R39]), and dampen both inflammation and AHR ([@R62]) in animal models of disease. On the other hand, targeting the kinase responsible for S1P generation has also shown promise. Using a specific inhibitor of SphK1 blocked both IgE production from human and murine B cells ([@R42]) as well as attenuated MC mediated AHR in vivo ([@R66]).

2.. Conclusions {#S10}
===============

Despite advances in our understanding of disease immunopathology, asthma remains a significant public health burden and a cause for morbidity and mortality worldwide. Sphingolipids play an important role in the susceptibility, initiation, and exacerbation of asthma and may be a key biomarker for identification of certain endotypes and a target for drug discovery. While this review focused on sphingolipid biology in the context of mast cells, sphingolipid have also been appreciated to play a critical role in other cellular mediators of asthma such as T cells, B cells, and airway smooth muscle cells thus better understanding of the complex role of sphingolipids in asthma may prove to yield effective therapeutics that target many facets of disease.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors for the compilation of this review article. This research is supported by National Institutes of Health grant R01AI50094 awarded to Sarah Spiegel.

Disclosures

None to report.

Appendix A. Supplementary data

Supplementary data related to this article can be found at <https://doi.org/10.1016/j.jbior.2018.09.001>.

![Model.](nihms-1509326-f0001){#F1}
